Publication: Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy
Issued Date
2013-02-01
Resource Type
ISSN
13993062
13982273
13982273
Other identifier(s)
2-s2.0-84873415399
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Transplant Infectious Disease. Vol.15, No.1 (2013)
Suggested Citation
W. Bosch, N. Poowanawittayakom, K. Chaikriangkrai, J. Mendez, W. C. Hellinger, T. A. Gonwa, M. Krishna, S. Pungpapong Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy. Transplant Infectious Disease. Vol.15, No.1 (2013). doi:10.1111/tid.12048 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32548
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Tuberculous hepatitis in renal transplant recipients following alemtuzumab induction therapy
Other Contributor(s)
Abstract
Mycobacterium tuberculosis infection is one of many opportunistic infections in renal transplant recipients, arising either from reactivation of latent infection or de novo infection, occasionally donor derived. M. tuberculosis hepatitis has never been reported in patients who have received alemtuzumab as part of their renal transplant management. We describe 2 patients who underwent deceased-donor renal transplantation following alemtuzumab induction therapy and presented with a febrile syndrome, subsequently diagnosed as tuberculous hepatitis, one with disseminated disease. Both responded well to treatment without significant side effects, resulting in excellent graft function. The importance of chemoprophylaxis should be emphasized to minimize the risk of developing active tuberculosis in patients with latent tuberculosis infection undergoing solid organ transplantation. © 2012 John Wiley & Sons A/S.